Alvimopan

證據等級: L5

預測適應症: 0 個

Alvimopan: Evaluation Report — No TxGNN Predictions Available

One-Sentence Summary

Alvimopan is a peripherally acting μ-opioid receptor antagonist, approved in the United States for accelerating gastrointestinal recovery following bowel resection surgery, but not currently marketed in Taiwan. The current Evidence Pack contains no TxGNN repurposing predictions for this drug, and critical inputs — including mechanism of action and safety data — remain unpopulated. A full repurposing assessment cannot be completed until these data gaps are resolved.

Quick Overview

Item	Content
Original Indication	GI recovery post-bowel resection (US-approved; not marketed in Taiwan)
Predicted New Indication	Not available
TxGNN Prediction Score	Not available
Evidence Level	L5 — Pending: TxGNN pipeline has not yet been executed for this drug
Taiwan Market Status	✗ Not Marketed
Number of Taiwan Licenses	0
Recommended Decision	Hold

Why Assessment Cannot Proceed

The Evidence Pack for Alvimopan (DB06274) is currently in an early-collection state. Three critical data layers are absent:

1. No repurposing predictions generated. The predicted_indications array is empty, meaning the TxGNN pipeline (knowledge-graph and deep-learning prediction steps) has not yet been run for this drug. Without a ranked list of candidate indications, there is no target to evaluate.

2. Mechanism of action unavailable. The original_moa field is unpopulated. Alvimopan’s known pharmacology — peripheral μ-opioid receptor antagonism — is directly relevant to any mechanistic plausibility analysis of new indications, particularly in GI motility disorders, opioid-induced constipation, or bowel recovery contexts. Retrieval from the DrugBank API is flagged as a high-severity remediation task (DG002).

3. Safety data absent. All warning and contraindication fields returned [Data Gap], and the DDI query returned no results. This prevents the mandatory S1 safety screen from being completed (DG001, classified as Blocking severity).

Taiwan Market Information

Alvimopan has no Taiwan FDA (TFDA) licenses on record. The drug is not marketed in Taiwan, and no dosage forms or approved indications exist in the local registry.

For reference, Alvimopan is marketed in the United States under the brand name Entereg (originally Adolor/GlaxoSmithKline, later acquired by Cubist/Merck), indicated for short-term in-hospital use to accelerate upper and lower GI recovery after partial large or small bowel resection with primary anastomosis.

Safety Considerations

Please refer to the package insert for safety information.

Note: DG001 is classified as Blocking severity. The TFDA package insert PDF must be retrieved and parsed before any safety-related evaluation can proceed.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack lacks both repurposing prediction output and the safety data required for the S1 screen. Proceeding with evaluation in this state would produce an unreliable assessment with no factual basis for a Go or Proceed-with-Guardrails recommendation.

To proceed, the following is needed:

[Blocking] Retrieve TFDA package insert PDF and extract key warnings and contraindications (DG001)
[High] Query DrugBank API for Alvimopan mechanism of action, pharmacodynamics, and toxicity data (DG002)
[Required] Execute the TxGNN knowledge-graph and deep-learning prediction pipeline for DB06274 to populate predicted_indications
[Optional] Re-run the DDI query against an updated interaction database to confirm the zero-interaction result is genuine rather than a lookup failure
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.